130 related articles for article (PubMed ID: 16697196)
1. Structure-activity relationships of 1,5-biaryl pyrroles as EP1 receptor antagonists.
Hall A; Atkinson S; Brown SH; Chessell IP; Chowdhury A; Clayton NM; Coleman T; Giblin GM; Gleave RJ; Hammond B; Healy MP; Johnson MR; Michel AD; Naylor A; Novelli R; Spalding DJ; Tang SP
Bioorg Med Chem Lett; 2006 Jul; 16(14):3657-62. PubMed ID: 16697196
[TBL] [Abstract][Full Text] [Related]
2. 1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists: Structure-activity relationships of 4- and 5-substituted benzoic acid derivatives.
Hall A; Brown SH; Chessell IP; Chowdhury A; Clayton NM; Coleman T; Giblin GM; Hammond B; Healy MP; Johnson MR; Metcalf A; Michel AD; Naylor A; Novelli R; Spalding DJ; Sweeting J
Bioorg Med Chem Lett; 2007 Feb; 17(3):732-5. PubMed ID: 17098427
[TBL] [Abstract][Full Text] [Related]
3. 1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists. Structure-activity relationships of 6-substituted and 5,6-disubstituted benzoic acid derivatives.
Hall A; Brown SH; Chessell IP; Chowdhury A; Clayton NM; Coleman T; Giblin GM; Hammond B; Healy MP; Johnson MR; Metcalf A; Michel AD; Naylor A; Novelli R; Spalding DJ; Sweeting J; Winyard L
Bioorg Med Chem Lett; 2007 Feb; 17(4):916-20. PubMed ID: 17175160
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel, non-acidic 1,5-biaryl pyrrole EP1 receptor antagonists.
Hall A; Atkinson S; Brown SH; Chessell IP; Chowdhury A; Giblin GM; Goldsmith P; Healy MP; Jandu KS; Johnson MR; Michel AD; Naylor A; Sweeting JA
Bioorg Med Chem Lett; 2007 Mar; 17(5):1200-5. PubMed ID: 17196385
[TBL] [Abstract][Full Text] [Related]
5. Discovery of GSK345931A: An EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain.
Hall A; Brown SH; Budd C; Clayton NM; Giblin GM; Goldsmith P; Hayhow TG; Hurst DN; Naylor A; Anthony Rawlings D; Scoccitti T; Wilson AW; Winchester WJ
Bioorg Med Chem Lett; 2009 Jan; 19(2):497-501. PubMed ID: 19036582
[TBL] [Abstract][Full Text] [Related]
6. Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy.
Hall A; Billinton A; Brown SH; Clayton NM; Chowdhury A; Giblin GM; Goldsmith P; Hayhow TG; Hurst DN; Kilford IR; Naylor A; Passingham B; Winyard L
Bioorg Med Chem Lett; 2008 Jun; 18(11):3392-9. PubMed ID: 18462938
[TBL] [Abstract][Full Text] [Related]
7. EP1 antagonists for the treatment of inflammatory pain.
Hall A; Billinton A; Giblin GM
Curr Opin Drug Discov Devel; 2007 Sep; 10(5):597-612. PubMed ID: 17786859
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel indole series of EP1 receptor antagonists by scaffold hopping.
Hall A; Billinton A; Brown SH; Chowdhury A; Giblin GM; Goldsmith P; Hurst DN; Naylor A; Patel S; Scoccitti T; Theobald PJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2684-90. PubMed ID: 18378447
[TBL] [Abstract][Full Text] [Related]
9. The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain.
Giblin GM; Bit RA; Brown SH; Chaignot HM; Chowdhury A; Chessell IP; Clayton NM; Coleman T; Hall A; Hammond B; Hurst DN; Michel AD; Naylor A; Novelli R; Scoccitti T; Spalding D; Tang SP; Wilson AW; Wilson R
Bioorg Med Chem Lett; 2007 Jan; 17(2):385-9. PubMed ID: 17084082
[TBL] [Abstract][Full Text] [Related]
10. Discovery of new chemical leads for selective EP1 receptor antagonists.
Naganawa A; Saito T; Nagao Y; Egashira H; Iwahashi M; Kambe T; Koketsu M; Yamamoto H; Kobayashi M; Maruyama T; Ohuchida S; Nakai H; Kondo K; Toda M
Bioorg Med Chem; 2006 Aug; 14(16):5562-77. PubMed ID: 16697646
[TBL] [Abstract][Full Text] [Related]
11. Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies.
Lambeng N; Lebon F; Christophe B; Burton M; De Ryck M; Quéré L
Bioorg Med Chem Lett; 2007 Jan; 17(1):272-7. PubMed ID: 17027269
[TBL] [Abstract][Full Text] [Related]
12. Novel methylene-linked heterocyclic EP1 receptor antagonists.
Hall A; Bit RA; Brown SH; Chowdhury A; Giblin GM; Hurst DN; Kilford IR; Lewell X; Naylor A; Scoccitti T
Bioorg Med Chem Lett; 2008 Mar; 18(5):1592-7. PubMed ID: 18262416
[TBL] [Abstract][Full Text] [Related]
13. Identification and optimization of novel 1,3,4-oxadiazole EP1 receptor antagonists.
Hall A; Brown SH; Chowdhury A; Giblin GM; Gibson M; Healy MP; Livermore DG; Wilson RJ; Naylor A; Rawlings DA; Roman S; Ward E; Willay C
Bioorg Med Chem Lett; 2007 Aug; 17(16):4450-5. PubMed ID: 17574410
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.
Giblin GM; O'Shaughnessy CT; Naylor A; Mitchell WL; Eatherton AJ; Slingsby BP; Rawlings DA; Goldsmith P; Brown AJ; Haslam CP; Clayton NM; Wilson AW; Chessell IP; Wittington AR; Green R
J Med Chem; 2007 May; 50(11):2597-600. PubMed ID: 17477516
[TBL] [Abstract][Full Text] [Related]
15. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis.
Clark P; Rowland SE; Denis D; Mathieu MC; Stocco R; Poirier H; Burch J; Han Y; Audoly L; Therien AG; Xu D
J Pharmacol Exp Ther; 2008 May; 325(2):425-34. PubMed ID: 18287210
[TBL] [Abstract][Full Text] [Related]
16. 2,3-Diarylthiophenes as selective EP1 receptor antagonists.
Ducharme Y; Blouin M; Carrière MC; Chateauneuf A; Côté B; Denis D; Frenette R; Greig G; Kargman S; Lamontagne S; Martins E; Nantel F; O'Neill G; Sawyer N; Metters KM; Friesen RW
Bioorg Med Chem Lett; 2005 Feb; 15(4):1155-60. PubMed ID: 15686932
[TBL] [Abstract][Full Text] [Related]
17. Potent bradykinin B1 receptor antagonists: 4-substituted phenyl cyclohexanes.
Su DS; Lim JL; Markowitz MK; Wan BL; Murphy KL; Reiss DR; Harrell CM; O'Malley SS; Ransom RW; Chang RS; Pettibone DJ; Tang C; Prueksaritanont T; Freidinger RM; Bock MG
Bioorg Med Chem Lett; 2007 Jun; 17(11):3006-9. PubMed ID: 17428657
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel biaryl heterocyclic EP1 receptor antagonists.
Hall A; Bit RA; Brown SH; Chaignot HM; Chessell IP; Coleman T; Giblin GM; Hurst DN; Kilford IR; Lewell XQ; Michel AD; Mohamed S; Naylor A; Novelli R; Skinner L; Spalding DJ; Tang SP; Wilson RJ
Bioorg Med Chem Lett; 2006 May; 16(10):2666-71. PubMed ID: 16503138
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists.
Nelson DW; Gregg RJ; Kort ME; Perez-Medrano A; Voight EA; Wang Y; Grayson G; Namovic MT; Donnelly-Roberts DL; Niforatos W; Honore P; Jarvis MF; Faltynek CR; Carroll WA
J Med Chem; 2006 Jun; 49(12):3659-66. PubMed ID: 16759108
[TBL] [Abstract][Full Text] [Related]
20. The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.
Blouin M; Han Y; Burch J; Farand J; Mellon C; Gaudreault M; Wrona M; Lévesque JF; Denis D; Mathieu MC; Stocco R; Vigneault E; Therien A; Clark P; Rowland S; Xu D; O'Neill G; Ducharme Y; Friesen R
J Med Chem; 2010 Mar; 53(5):2227-38. PubMed ID: 20163116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
